Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

Last updated:
2026-07-18
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB MONOTHERAPY VERSUS STANDARD OF CARE IN PARTICIPANTS WITH UNTREATED T4N0 OR STAGE III DMMR/MSI-H RESECTABLE COLON CANCER

Intervention/treatment:
JEMPERLI
Medical condition:
COLON CANCER
Protocol code:
219606
Control number:
274720
Status:
Recruiting
Approved:
May 31, 2023
Trial phase:
Phase 3
For more information:
ClinicalTrials.gov - NCT05855200
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
18 Years and older
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
US GSK Clinical Trials Call Center
Role
CONTACT
Phone:
877-379-3718
Name
EU GSK Clinical Trials Call Center
Role
CONTACT
Phone:
+44 (0) 20 89904466
Sponsor
GLAXOSMITHKLINE INC

Locations

Alberta

GSK Investigational Site
Edmonton, Alberta, T6G 1Z2
WITHDRAWN

Nova Scotia

GSK Investigational Site
Halifax, Nova Scotia, B3H 1V7
Recruiting
Name
US GSK Clinical Trials Call Center
Role
CONTACT
Phone:
877-379-3718
Name
EU GSK Clinical Trials Call Centre
Role
CONTACT
Phone:
+44 (0) 20 8990 4466
Name
Katerina Neumann
Role
PRINCIPAL_INVESTIGATOR

Ontario

GSK Investigational Site
Ottawa, Ontario, K1H 8L6
Recruiting
Name
US GSK Clinical Trials Call Center
Role
CONTACT
Phone:
877-379-3718
Name
EU GSK Clinical Trials Call Centre
Role
CONTACT
Phone:
+44 (0) 20 8990 4466
Name
Rebecca Auer
Role
PRINCIPAL_INVESTIGATOR
GSK Investigational Site
Toronto, Ontario, M5G 2M9
Recruiting
Name
US GSK Clinical Trials Call Center
Role
CONTACT
Phone:
877-379-3718
Name
EU GSK Clinical Trials Call Centre
Role
CONTACT
Phone:
+44 (0) 20 8990 4466
Name
Eric Chen
Role
PRINCIPAL_INVESTIGATOR

Quebec

GSK Investigational Site
Montreal, Quebec, H4A 3J1
Recruiting
Name
US GSK Clinical Trials Call Center
Role
CONTACT
Phone:
877-379-3718
Name
EU GSK Clinical Trials Call Centre
Role
CONTACT
Phone:
+44 (0) 20 8990 4466
Name
Jamil Asselah
Role
PRINCIPAL_INVESTIGATOR
Did you find what you were looking for?

Contacts and resources